|Other Names||Nucleolysin TIA-1 isoform p40, RNA-binding protein TIA-1, T-cell-restricted intracellular antigen-1, TIA-1, p40-TIA-1, TIA1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1830c was selected from the Center region of human TIA1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Involved in alternative pre-RNA splicing and regulation of mRNA translation by binding to AU-rich elements (AREs) located in mRNA 3' untranslated regions (3' UTRs). Possesses nucleolytic activity against cytotoxic lymphocyte target cells. May be involved in apoptosis.|
|Cellular Location||Cytoplasmic granule. Nucleus Note=Accumulates in cytoplasmic stress granules (SG) following cellular damage.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
TIA1 is a member of a RNA-binding protein family and possesses nucleolytic activity against cytotoxic lymphocyte (CTL) target cells. It has been suggested that this protein may be involved in the induction of apoptosis as it preferentially recognizes poly(A) homopolymers and induces DNA fragmentation in CTL targets. The major granule-associated species is a 15-kDa protein that is thought to be derived from the carboxyl terminus of the 40-kDa product by proteolytic processing.
Yeowell,H.N., Walker,L.C. J. Invest. Dermatol. 129 (6), 1402-1411 (2009)Eisinger-Mathason,T.S. Mol. Cell 31 (5), 722-736 (2008)Tang,H., Huang,Y. Intervirology 51 (3), 203-209 (2008)Dember,L.M., Kim,N.D. J. Biol. Chem. 271 (5), 2783-2788 (1996)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.